As of 2025-08-11, the EV/EBITDA ratio of Nurix Therapeutics Inc (NRIX) is -3.14. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NRIX's latest enterprise value is 668.01 mil USD. NRIX's TTM EBITDA according to its financial statements is -212.78 mil USD. Dividing these 2 quantities gives us the above NRIX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.7x - 17.1x | 14.2x |
| Forward P/E multiples | 22.5x - 31.2x | 26.3x |
| Fair Price | (61.41) - (46.44) | (55.26) |
| Upside | -724.1% - -571.9% | -661.6% |
| Date | EV/EBITDA |
| 2025-08-08 | -3.14 |
| 2025-08-07 | -3.22 |
| 2025-08-06 | -3.36 |
| 2025-08-05 | -3.67 |
| 2025-08-04 | -3.66 |
| 2025-08-01 | -3.57 |
| 2025-07-31 | -3.65 |
| 2025-07-30 | -3.87 |
| 2025-07-29 | -3.88 |
| 2025-07-28 | -3.89 |
| 2025-07-25 | -3.74 |
| 2025-07-24 | -3.75 |
| 2025-07-23 | -3.78 |
| 2025-07-22 | -3.65 |
| 2025-07-21 | -3.65 |
| 2025-07-18 | -3.63 |
| 2025-07-17 | -3.95 |
| 2025-07-16 | -4.07 |
| 2025-07-15 | -3.97 |
| 2025-07-14 | -4.16 |
| 2025-07-11 | -4.07 |
| 2025-07-10 | -4.16 |
| 2025-07-09 | -4.34 |
| 2025-07-08 | -3.99 |
| 2025-07-07 | -4.04 |
| 2025-07-03 | -4.18 |
| 2025-07-02 | -4.07 |
| 2025-07-01 | -3.81 |
| 2025-06-30 | -3.70 |
| 2025-06-27 | -3.79 |
| 2025-06-26 | -3.86 |
| 2025-06-25 | -3.78 |
| 2025-06-24 | -3.90 |
| 2025-06-23 | -3.91 |
| 2025-06-20 | -3.73 |
| 2025-06-18 | -3.78 |
| 2025-06-17 | -3.70 |
| 2025-06-16 | -3.88 |
| 2025-06-13 | -3.89 |
| 2025-06-12 | -3.90 |
| 2025-06-11 | -4.14 |
| 2025-06-10 | -4.20 |
| 2025-06-09 | -4.11 |
| 2025-06-06 | -4.20 |
| 2025-06-05 | -4.10 |
| 2025-06-04 | -3.97 |
| 2025-06-03 | -3.94 |
| 2025-06-02 | -3.97 |
| 2025-05-30 | -3.42 |
| 2025-05-29 | -3.43 |